Zimmer Biomet (NYSE:ZBH) Cut to “Hold” at Baird R W

Baird R W downgraded shares of Zimmer Biomet (NYSE:ZBH) from a strong-buy rating to a hold rating in a report published on Tuesday morning,Zacks.com reports.

Several other research firms also recently issued reports on ZBH. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Robert W. Baird reaffirmed a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday. Rothschild & Co Redburn began coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They set a “buy” rating and a $130.00 target price for the company. UBS Group lowered their target price on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a report on Thursday, November 6th. Finally, Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $107.50.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $90.39 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The stock has a 50-day moving average of $95.07 and a 200-day moving average of $96.65. The company has a market cap of $17.91 billion, a PE ratio of 22.37, a P/E/G ratio of 2.41 and a beta of 0.61. Zimmer Biomet has a one year low of $85.33 and a one year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts predict that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s payout ratio is presently 23.76%.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Zimmer Biomet by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after purchasing an additional 198,370 shares during the last quarter. Dodge & Cox grew its position in Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after buying an additional 1,118,710 shares during the period. Capital International Investors increased its holdings in Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares during the last quarter. American Century Companies Inc. raised its position in Zimmer Biomet by 8.7% in the second quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after acquiring an additional 458,903 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Zimmer Biomet by 1.4% in the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after acquiring an additional 69,485 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.